Browse Studies — Arctuva

Phase 3

A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)

This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of ev…

Treatment-resistant Schizophrenia

Estimated

~$10 – $8,750

Newron Pharmaceuticals SPANCT07184619

Observational

Real-time fMRI Neurofeedback as a Tool to Mitigate Auditory Hallucinations in Patients With Schizophrenia - R33 Phase

Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the …

SchizophreniaAuditory HallucinationTreatment-resistant Schizophrenia

Estimated

~$10 – $8,750

Boston VA Research Institute, Inc.NCT05299749

Observational

Deep Brain Stimulation in Treatment Resistant Schizophrenia

The purpose of this pilot study is to investigate the use of deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr) in subjects with treatm…

Treatment-resistant Schizophrenia

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT02361554